53606-33-0Relevant articles and documents
Three-Dimensional Heterocycles by Iron-Catalyzed Ring-Closing Sulfoxide Imidation
Yu, Hao,Li, Zhen,Bolm, Carsten
supporting information, p. 12053 - 12056 (2018/09/11)
A general and atom-economical method for the synthesis of cyclic sulfoximines by intramolecular imidations of azido-containing sulfoxides using a commercially available FeII phthalocyanine (FeIIPc) as catalyst has been developed. The method conveys a broad functional group tolerance and the resulting three-dimensional heterocycles can be modified by cross-coupling reactions.
Synthesis and fungicidal activities of novel benzothiophene-substituted oxime ether strobilurins
Tu, Song,Xie, Ya-Qiang,Gui, Si-Zhe,Ye, Li-Yi,Huang, Zi-Long,Huang, Yi-Bing,Che, Li-Ming
supporting information, p. 2173 - 2176 (2014/05/06)
Twenty-one novel benzothiophene-substituted oxime ether strobilurins, which employed a benzothiophene group to stabilise the E-styryl group in Enoxastrobin (an unsaturated oxime strobilurin fungicide developed by Shenyang Research Institute of Chemical Industry, China) were designed and synthesised. The biological assay indicated that most compounds exhibited good or excellent fungicidal activities, especially against Colletotrichum lagenarium and Puccinia sorghi Schw. In addition, methyl 3-methoxypropenoate oxime ethers and N-methoxy-carbamic acid methyl esters exhibited good in vivo fungicidal activities against Erysiphe graminis, Colletotrichum lagenarium and Puccinia sorghi Schw. under the tested concentrations. Notably, (E,E)-methyl 3-methoxy-2-(2-((((6-chloro-1-(1H-benzo[b]thien-2-yl)ethylidene)amino)oxy) methyl)phenyl)propenoate (5E) exhibited more potent in vivo fungicidal activities against nearly all of the tested fungi at a concentration of 0.39 mg/L compared to Enoxastrobin.
New CRTH2 Antagonists
-
Page/Page column 38, (2012/12/13)
The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.